Taro entered the U.S. market in 1988, after establishing its Canadian subsidiary in 1984 and receiving approval of its first topical product in the United States.
The U.S. has become Taro’s largest market, accounting for more than 80% of our global sales. Our proprietary and generic U.S. products are both prescription and over-the-counter (OTC) medications, sold in Taro label and private-label (store brand). They include topical dermatological prescription pharmaceuticals (creams, ointments, gels, etc.), a category in which Taro is an acknowledged leader, as well as a growing line of oral dose drugs (tablets and capsules) used primarily in cardiovascular and neurological disorders.
Taro U.S.A. maintains its own distribution facilities so that our U.S. customers, which include the largest drugstore chains and wholesalers, are assured of a continuous supply of Taro products. Taro's first U.S. research operations were established in 2003.
We invite you to return to this website often – you’ll find new products and new information all the time. If you have any question that is not answered on this site, please contact us.
Thank you for your interest in Taro.